Harrison S N, Autelitano D J, Wang B H, Milano C, Du X J, Woodcock E A
Cellular Biochemistry, Molecular Physiology and Experimental Cardiology Laboratories, Baker Medical Research Institute, Melbourne, Victoria, Australia.
Circ Res. 1998;83(12):1232-40. doi: 10.1161/01.res.83.12.1232.
Reperfusion of globally ischemic rat hearts causes the generation of inositol(1,4,5)trisphosphate [Ins(1,4,5)P3] and the initiation of arrhythmias. These responses are mediated by alpha1-adrenergic receptors (ARs), but the subtype of receptor involved has not been identified. Under normoxic conditions, hearts from transgenic animals expressing constitutively active alpha1B-ARs in heart (alpha1B-constitutively active mutant [CAM]) showed higher [3H] inositol phosphate responses to norepinephrine (2.3-fold) than hearts from nontransgenic animals (alpha1B-WT) (1.6-fold). alpha1B-WT hearts responded to 2 minutes of reperfusion after 20 minutes of global ischemia by generation of Ins(1,4,5)P3 (5301+/-1310 to 11 413+/-1597 CPM/g tissue; mean+/-SEM; n=6; P<0.01 in [3H] labeling studies and 3.8+/-0.2 to 6.3+/-0.6 nmol/g by mass analysis, n=6; P<0.05). In contrast to findings in normoxia, hearts from alpha1B-CAM animals showed no Ins(1,4,5)P3 response in early reperfusion. In parallel studies, alpha1B-WT hearts developed ventricular tachycardia and ventricular premature beats (VPB) during 5 minutes of reperfusion after 20 minutes of ischemia. The incidence of these arrhythmias was reduced in the alpha1B-CAM hearts (95% to 62% for VPB and 47% to 12% for ventricular tachycardia; both P<0.05). The resistance of the alpha1B-CAM hearts was not due to alpha1B-AR-mediated preconditioning, as the Ins(1,4,5)P3 response to thrombin receptor activation during reperfusion was not different between the 2 groups. To investigate the possibility of reduced alpha1A-receptor activity in the alpha1B-CAM hearts, expression of the mRNA for alpha1A- and alpha1B-receptors was measured. alpha1B-WT hearts contained mRNA for both receptor subtypes, but the levels of alpha1B-receptor mRNA were 5-fold higher than alpha1A-receptor mRNA. alpha1B-CAM hearts contained very high levels of alpha1B-receptor mRNA (26-fold increase), but the expression of mRNA for the alpha1A-receptors (0.141+/-0.035 amol/ microg RNA; mean+/-SEM; n=6) was reduced by 50% relative to alpha1B-WT controls (0.276+/-0.046 amol/ microg RNA; n=6; P<0.01). The reduction in arrhythmogenic and Ins(1,4,5)P3 responses in alpha1B-CAM hearts provides evidence that these response are not mediated by alpha1B-receptors.
全脑缺血大鼠心脏再灌注会导致肌醇(1,4,5)三磷酸[Ins(1,4,5)P3]的生成及心律失常的发生。这些反应由α1-肾上腺素能受体(ARs)介导,但具体涉及的受体亚型尚未明确。在常氧条件下,心脏中组成型表达活性α1B-ARs的转基因动物(α1B-组成型活性突变体[CAM])的心脏对去甲肾上腺素的[3H]肌醇磷酸反应(2.3倍)高于非转基因动物(α1B-WT)的心脏(1.6倍)。α1B-WT心脏在全脑缺血20分钟后再灌注2分钟时,通过生成Ins(1,4,5)P3产生反应([3H]标记研究中为5301±1310至11413±1597 CPM/g组织;平均值±标准误;n = 6;P<0.01;质量分析中为3.8±0.2至6.3±0.6 nmol/g,n = 6;P<0.05)。与常氧条件下的结果相反,α1B-CAM动物的心脏在早期再灌注时未出现Ins(1,4,5)P3反应。在平行研究中,α1B-WT心脏在缺血20分钟后的再灌注5分钟内出现室性心动过速和室性早搏(VPB)。这些心律失常的发生率在α1B-CAM心脏中降低(VPB从95%降至62%,室性心动过速从47%降至12%;两者P<0.05)。α1B-CAM心脏的抗性并非由于α1B-AR介导的预处理,因为两组在再灌注期间对凝血酶受体激活的Ins(1,4,5)P3反应并无差异。为研究α1B-CAM心脏中α1A-受体活性降低的可能性,检测了α1A-和α1B-受体的mRNA表达。α1B-WT心脏含有两种受体亚型的mRNA,但α1B-受体mRNA水平比α1A-受体mRNA高5倍。α1B-CAM心脏含有非常高水平的α1B-受体mRNA(增加26倍),但α1A-受体的mRNA表达(0.141±0.035 amol/μg RNA;平均值±标准误;n = 6)相对于α1B-WT对照(0.276±0.046 amol/μg RNA;n = 6;P<0.01)降低了50%。α1B-CAM心脏中致心律失常和Ins(1,4,5)P3反应的降低提供了证据,表明这些反应并非由α1B-受体介导。